| __timestamp | Dynavax Technologies Corporation | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 504755000 |
| Thursday, January 1, 2015 | 22180000 | 838526000 |
| Friday, January 1, 2016 | 37257000 | 1177697000 |
| Sunday, January 1, 2017 | 27367000 | 1320433000 |
| Monday, January 1, 2018 | 64770000 | 1556200000 |
| Tuesday, January 1, 2019 | 74986000 | 1834800000 |
| Wednesday, January 1, 2020 | 79256000 | 1346000000 |
| Friday, January 1, 2021 | 100156000 | 1824900000 |
| Saturday, January 1, 2022 | 131408000 | 2115900000 |
| Sunday, January 1, 2023 | 152946000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Cracking the code
In the competitive world of biotechnology, understanding spending patterns can offer valuable insights into a company's strategic priorities. Over the past decade, Regeneron Pharmaceuticals, Inc. and Dynavax Technologies Corporation have demonstrated contrasting approaches to their Selling, General, and Administrative (SG&A) expenses.
Regeneron, a leader in the biotech industry, has consistently increased its SG&A spending, peaking at approximately $2.63 billion in 2023. This represents a staggering 420% increase from 2014, reflecting its aggressive expansion and market penetration strategies. In contrast, Dynavax's SG&A expenses grew by 760% over the same period, reaching around $153 million in 2023. This rapid increase highlights Dynavax's efforts to bolster its market presence and operational capabilities.
These spending patterns underscore the dynamic nature of the biotech sector, where strategic investments in SG&A can significantly influence a company's growth trajectory.
SG&A Efficiency Analysis: Comparing Sanofi and Dynavax Technologies Corporation
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Regeneron Pharmaceuticals, Inc. and Walgreens Boots Alliance, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Alpine Immune Sciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Pharming Group N.V.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Grifols, S.A.
Regeneron Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.: SG&A Expense Trends
Regeneron Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
argenx SE and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Protagonist Therapeutics, Inc. vs Dynavax Technologies Corporation